



CS/BSE/NSE/2019-2020

January 10, 2020

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Outcome of Board Meeting – Intimation of Record Date pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref.: Our letter dated January 7, 2020 regarding approval of the Composite Scheme of Arrangement (Demerger) under Sections 230 to 232 read with Section 66 and other applicable provisions of the Companies Act, 2013 amongst Suven Life Sciences Limited (SLSL) (“Demerged Company”) and Suven Pharmaceuticals Limited (SPL) (“Resulting Company”) and their respective Shareholders and Creditors.

.....

With reference to the above subject, pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 10th January, 2020, has taken on record and approved the following matter:

We wish to inform you that consequent to Scheme of Arrangement (Demerger) sanctioned by the Hon'ble National Company Law Tribunal, Bench at Hyderabad ("NCLT") the said scheme became operational w.e.f. 9th January, 2020 having consideration of the transfer and vesting of the of Demerged Undertaking (as defined in the Scheme) from SLSL to SPL in terms of the Scheme, the Equity Shareholders of the Company whose names recorded in the Register of Members and records of the depositories as a member of the Company as on **Wednesday, January 22, 2020** being the Record Date fixed by the Board, will be entitled for allotment of:

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

“1 (One) fully paid up Equity Share of face value of INR 1/- (Rupee One Only) each of Suven Pharmaceuticals Limited (Resulting Company) shall be issued and allotted for every 1 (One) fully paid up equity share of face value of INR 1/- (Rupee One Only) each held in Suven Life Sciences Limited (Demerged Company)”

The disclosure of the Record Date in the tabular format is as below:

Scrip Code and ID/ Scrip Symbol	Type of security	Book Closure both days inclusive	Record date	Purpose
1. BSE: Scrip Code: 530239	Equity shares	Not Applicable	January 22, 2020	Determining the entitlement of equity shareholders of Suven Life Sciences Limited (SLSL) for the purpose of issue and allotment of fully paid up equity shares of Rs. 1.00 each Suven Pharmaceuticals Limited (SPL) in terms of the Scheme.
2. NSE Scrip Symbol: SUVEN				

No fractional Share certificates will be issued.

After the issuance and allotment of the Equity Shares by Suven Pharmaceuticals Limited, the SPL will complete the necessary steps to have the Equity Shares listed on the BSE Limited and National Stock Exchange of India Limited.

This is for your information and record.

Thanking You,
Yours faithfully,
For **Suven Life Sciences Limited**



K. Hanumantha Rao
Company Secretary

Copy to:

National Securities Depository Ltd.
4th Floor, A Wing,
Trade World,
Kamala Mills Compound
Senapati Bapat Marg
Lower Parel
Mumbai- 400013

**Central Depository Services
(India) Limited**
25th Floor, Marathon
Futurex, N M Joshi Marg,
Lower Parel (East)
Mumbai- 400001

**KFin Technologies Private
Limited**
Karvy Selenium Tower B,
Plot 31-32, Gachibowli,
Financial District
Nanakramguda, Hyderabad –
500032

Suven Life Sciences Limited